Pharming Group NV ADR(PHAR) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:00 PM ET (Korea 10/31 05:00)
Full metrics table
| Index | - | P/E | 38.83 | EPS (ttm) | 0.32 | Insider Own | - | Shs Outstand | 70.8M | Perf Week | 9.2% |
| Market Cap | 0.87B | Forward P/E | 41.84 | EPS next Y | -2.05% | Insider Trans | - | Shs Float | - | Perf Month | 22.91% |
| Enterprise Value | 0.79B | PEG | 0.31 | EPS next Q | 0.1 | Inst Own | 1.31% | Short Float | - | Perf Quarter | 24.54% |
| Income | 0.02B | P/S | 2.24 | EPS this Y | 646% | Inst Trans | -6.35% | Short Ratio | 0.54 | Perf Half Y | -27.97% |
| Sales | 0.39B | P/B | 2.97 | EPS next 5Y | 136.63% | ROA | 4.95% | Short Interest | 0.01M | Perf YTD | -30.79% |
| Book/sh | 4.11 | P/C | 4.57 | EPS past 3/5Y | -41.84% -41.23% | ROE | 8.65% | 52W High | -42.69% ($21.34) | Perf Year | -6.93% |
| Cash/sh | 2.68 | P/FCF | 30.9 | Sales past 3/5Y | 22.4% 12.25% | ROIC | 6.06% | 52W Low | 34.25% ($9.11) | Perf 3Y | 12.2% |
| Dividend Est. | - | EV/EBITDA | 17.06 | EPS Y/Y TTM | 2242.07% | Gross Margin | 82.77% | Volatility(W/M) | 3.34% 3.23% | Perf 5Y | 35.89% |
| Dividend TTM | - | EV/Sales | 2.04 | Sales Y/Y TTM | 6.67% | Oper. Margin | 8.84% | ATR (14) | 0.46 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 2.65 | EPS Q/Q | 174.95% | Profit Margin | 6.22% | RSI (14) | 70.11 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.23 | Sales Q/Q | 21.29% | SMA20 | 18.22% ($10.35) | Beta | -0.02 | Target Price | $30.17 |
| Payout | - | Debt/Eq | 0.39 | Earnings | 2026/10/27 | SMA50 | 14.16% ($10.71) | Rel Volume | 0.56 | Prev Close | $12.13 |
| Employees | - | LT Debt/Eq | 0.36 | EPS/Sales Surpr. | 42.86% - | SMA200 | -11.26% ($13.78) | Avg Volume(3M) | 0.03M | Price | $12.23 |
| IPO | 2020/12/23 | Option/Short | No/Yes | Trades | 117 | Volume | 14,053 | Change | 0.82% |
💊 Pharming Group (PHAR) is a Netherlands-based biopharmaceutical company focused on treatments for rare diseases. It commercializes RUCONEST, a therapy for acute attacks of hereditary angioedema, and Joenja (leniolisib), a treatment for activated phosphoinositide 3-kinase delta syndrome (an ultra-rare immune disorder), primarily in the United States. The company is growing on the back of high gross margins and deep expertise in rare diseases. Listed in the U.S. as an ADR, the stock is accessible to global investors.
Over the past 1 year, roughly in the middle
43% below its 1-year high.
Traded less than usual. That is 56% of its average volume.
PHAR makes money exceptionally well
Of every $100 in sales, $8.84 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +646.0% this year.
Tap to view numbers
The price is about the industry average
For a company expected to earn $100 next year, you would pay $4,184. Peers typically go for $1,477.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +35.9%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Institutions barely hold it
Institutions hold 1.3%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
EWN iShares MSCI Netherlands ETF <0.01% 
FDTS First Trust Developed Markets ex-US Small Cap AlphaDEX Fund <0.01% 
GWX State Street SPDR S&P International Small Cap ETF <0.01% 
IEUS iShares MSCI Europe Small-Cap ETF <0.01% 
BAMD Brookstone Dividend Stock ETF <0.01% Special products that amplify (leveraged) or invert this single stock. They decay quickly and are not for long-term holding.
IHE iShares U.S. Pharmaceuticals ETF 1.6B 
PBPH Portfolio Building Block World Pharma and Biotech Index ETF 1.2B 
FTXH First Trust Nasdaq Pharmaceuticals ETF 1.2B 
PPH VanEck Pharmaceutical ETF 1.1B 
PJP Invesco Pharmaceuticals ETF 573M It ranks #171 of 597 in the industry
Based on market cap of $866M.
ANRO#168 Alto Neuroscience Inc $887M PER - 
AKTS#169 Aktis Oncology Inc $886M PER - 
IVA#170 Inventiva ADR $868M PER - PHAR#171 Pharming Group NV ADR $866M PER 38.8 
PRME#172 Prime Medicine Inc $856M PER - 
FAQ
What kind of company is PHAR?
PHAR belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of PHAR?
The market cap of PHAR is approximately $866M, ranking 2,693 within its sector.
What is the P/E ratio of PHAR?
PHAR has a P/E ratio of approximately 38.8x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for PHAR?
PHAR has recorded a 52-week high of $21.34 and a low of $9.11.
